DB05778InvestigationalSmall molecule
COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. It is a believed to reduce erythema by constricting... It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
- Primary indication
- Investigated for use/treatment in skin infections/disorders.Curator reviewed
- Code names
- Col-118
What you can answer from here — as of April 23, 2025
Which companies are running trials of Col-118, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account